May 6, 2026 · 5 min read

CEP vs. US DMF: which filing, which market

CEP, US DMF and ASMF solve the same problem differently. Which one you need depends on where you're filing. A quick map for regulatory and sourcing teams.


An API's confidential manufacturing detail has to reach the regulator without passing through the buyer. Three mechanisms do this in different jurisdictions (the CEP, the US DMF and the ASMF), and confusing them costs time. Here is the short map.

US DMF (United States)

A Type II Drug Master File filed with the FDA. It is reviewed only when your application references it, and you need a Letter of Authorization from the API maker to do so. It is the route for the US market.

CEP (Europe, and beyond)

The Certificate of Suitability, issued by the EDQM, certifies that an API is adequately controlled by the relevant European Pharmacopoeia monograph. Unlike a DMF, a CEP is actively assessed and granted, so it carries a certificate you can point to. It is widely accepted across the EU and by many regulators worldwide that recognise EDQM, which makes it powerful for multi-market strategies.

ASMF (Europe, where no CEP exists)

The Active Substance Master File is the European analogue of the DMF: a two-part dossier (open + restricted) used when a molecule has no CEP. Like the DMF it needs a letter of access and is assessed in the context of your marketing authorisation application.

Which do you need?

  • Filing in the US → US DMF (with an LoA).
  • Filing in the EU → CEP if one exists for the molecule; otherwise an ASMF (with a letter of access).
  • Multi-market → a CEP plus a US DMF covers the two largest regulated markets and many that recognise EDQM.
  • Always confirm the filing covers the exact grade, route and site of the material you will buy. A certificate for a different route does not help you.

Several BOOKPHARM products carry a CEP, a US DMF, or both, each stated on its product page exactly as filed. Tell us your target markets and molecule and we will confirm which filings apply.